Thor Industries Inc. (NYSE:THO) shares fell -0.19% in last trading session and ended the day at $53.09. THO Gross Margin is 13.90% and its has a return on assets of 13.50%. Thor Industries Inc. (NYSE:THO) quarterly performance is -4.05%.
Thor Industries (NYSE: THO) declared a quarterly dividend of $0.27 per share, or $1.08 annualized. This is up from $0.24 prior. The dividend will be payable on October 30, 2015, to stockholders of record on October 16, 2015, with an ex-dividend date of October 14, 2015.
XBiotech, Inc. (NASDAQ:XBIT) ended the last trading day at $15.62. Company weekly volatility is calculated as 11.43% and price to cash ratio as 4.27. XBiotech, Inc. (NASDAQ:XBIT) showed a weekly performance of -2.62%.
XBiotech Inc. (NASDAQ:XBIT) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for its novel True Human monoclonal antibody therapy intended to treat all forms of Staphylococcus aureus infections, including Methicillin-resistant S. aureus (MRSA).
On 06 October, The Bank of New York Mellon Corporation (NYSE:BK) shares fell -0.47% and was closed at $39.96. BK EPS growth in last 5 year was 33.90%. The Bank of New York Mellon Corporation (NYSE:BK) year to date (YTD) performance is -0.26%.
Gerald L. Hassell, chairman and chief executive officer, and Thomas P. Gibbons, vice chairman and chief financial officer, along with other members of the executive management team from The Bank of New York Mellon Corporation (NYSE:BK) will host a conference call and simultaneous live audio webcast at 8 a.m. EDT on Tuesday, October 20, 2015, following th release of BNY Mellon’s third-quarter 2015 financial results at approximately 6:30 a.m. EDT that day.
Repligen Corporation (NASDAQ:RGEN) shares fell -10.12% in last trading session and ended the day at $25.66. RGEN Gross Margin is 57.10% and its has a return on assets of 5.80%. Repligen Corporation (NASDAQ:RGEN) quarterly performance is -35.41%.
On 15 September, Repligen Corporation (NASDAQ:RGEN) announced that life sciences industry veteran Glenn P. Muir has been elected to its Board of Directors and appointed as a member of its Audit Committee. Mr. Muir brings over 30 years of experience to the director role, most recently as Chief Financial Officer and Executive Vice President, Finance and Administration for Hologic, Inc. (HOLX), a large multi-national medical device and diagnostics company where he was instrumental to the company’s significant expansion.
Aeterna Zentaris Inc. (NASDAQ:AEZS) caters to the Healthcare space. Its weekly performance is -7.00%. On the last day of trading company shares ended up at $0.09. Aeterna Zentaris Inc. (NASDAQ:AEZS) distance from 50-day simple moving average (SMA50) is -18.13%.
On 28 September, Aeterna Zentaris Inc. (NASDAQ:AEZS) announced that its lead oncology compound, zoptarelin doxorubicin (formerly AEZS‑108), met the primary end-point of the investigator-driven and sponsored Phase 2 clinical trial in Castration and taxane Resistant Prostate Cancer (CRPC) and demonstrated good tolerability. The primary endpoint was Clinical Benefit (CB) defined as remaining progression-free by RECIST and Prostate Specific Antigen (PSA) after treatment for 12+ weeks.
Leave a Reply